Status:
ACTIVE_NOT_RECRUITING
Surveillance or Focal Therapy
Lead Sponsor:
Kaiser Permanente
Conditions:
Prostate Cancer
Eligibility:
MALE
40-80 years
Phase:
NA
Brief Summary
Patients with newly diagnosed low-intermediate risk prostate cancer often are not advised of all the options in an easy to understand way. This trial will show patients a 2 minute animated Explainer v...
Detailed Description
Low risk prostate cancer is usually monitored with active surveillance (AS). Some evidence suggests no differences in health-related quality of life (HRQoL) and wellness between men undergoing AS and ...
Eligibility Criteria
Inclusion
- Gleason 3+3 (GG 1) or 3+4 (GG2)
- ≤4 cores
- T1c-T2
- Prostate \< 60cc
- MRI non-focal or PIRADS 3-4 in peripheral gland
- Absence of significant anterior disease
Exclusion
- Anal stenosis
- Prostatic calfcifations
- Latex allergy
- Gleason grade group 3-5
- Multifocal or anterior disease
- Prostate \> 60 cc
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07207902
Start Date
June 1 2025
End Date
December 1 2026
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente
Los Angeles, California, United States, 90027